Novel therapy minimizes brain injury caused by CAR T cell therapies
Researchers demonstrated the efficacy of a novel treatment for the treatment of controlled acute myelogenous leukemia (CML) with the use of a novel CAR T cell therapy.
The CML gene is found in humans and was discovered by means of CRISPR-Cas9 genome editing.
Currently patients are treated with infusions of fetal blood containing antibodies that target the receptor involved in this response, which is capable of regulating the amount of tumor cells destroyed and enabling them to control blood pressure to a very high level.
Eckle, it was discovered that the brain, particularly the choroid plexus, undergoes a transformation because white blood cells no longer respond to the direct effect of the immune system.
As a consequence these cells leave the brain presenting a natural defense against any uncontrolled tumor growth. Continue reading